News | October 25, 2023
Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
hey were educated about the 7- step hand-washing technique trainings
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Over 34 lakh children and 6 lakh pregnant women were administered vaccine doses during the first 2 rounds of IMI 5.0 campaign across the country
Ayush Minister launched month long ayurveda celebration drive of Ministry of Ayush
Eni will guarantee Dompé researchers access to its laboratories, support from the company's specialized staff, and use of its HPC5 supercomputer
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Clinical Trial Data Services supports small to midsize sponsor companies helping them to take the next step towards market approval for their drug or device product.
Subscribe To Our Newsletter & Stay Updated
